Thryv Therapeutics is a genetic disorder that causes a prolongation between the beginning of the QRS complex and the end of the T waveQ and T waves on the EKG, indicating a prolongation of ventricular repolarization and the action potential duration. The lengthening of this complex is associated with unexpected and life-threatening ventriculararrhythmias. Click below to learn more about our programs.

Biotechnology

Therapeutics

Thryv Therapeutics

Paul F. Truex

Daphne Doucet

Curtis Mcgrath

Alexandre Brkovic

Marc Vidal

Eric Campeau

Aidan McNeil

Philip Sager

Debra Odink

Research and Development

Corporate Governance

Leadership Team

Teams at Thryv Therapeutics

Research and Development

Corporate Governance

Leadership Team